India's BDR Pharmaceuticals, Russia's Pharmasyntez to build plant in Kaluga region

KALUGA. Dec 5 (Interfax) - India's BDR Pharmaceuticals, Russia's JSC Pharmasyntez, and the Kaluga regional government have signed a trilateral agreement to build a high-tech active pharmaceutical ingredient factory in the region, the Kaluga region's governor Vladislav Shapsha said on Telegram.

"Both companies are among the pharmaceutical industry leaders. It is important for us that the joint venture will be built in our region, producing competitive drugs and improving drug safety," Shapsha said.

The plant plans to produce active pharmaceutical ingredients, including for the treatment of oncological diseases. The investment and project timeframe were not specified.

BDR Pharmaceuticals says on its website that it was founded in 2003 and specializes in the development and production of drugs and active pharmaceutical ingredients. BDR focuses on development in four specialized therapeutic segments: oncology, critical care, gynecology and neurology.

Pharmasyntez develops and manufactures oncology, hematology, endocrinology, immunology and cardiology medications, as well as drugs for the treatment of orphan, hormonal, infectious, autoimmune and cardiovascular diseases. The company's portfolio includes medications for the treatment of diabetes, tuberculosis, hepatitis, HIV, Covid-19 and chronic kidney disease.

The Pharmasyntez Group's has five plants located in Ussuriysk, Irkutsk, Bratsk, Tyumen and St. Petersburg. Annual production exceeds 100 million packages. The group's parent company, JSC Pharmasyntez, is located in Irkutsk.